Molecular Templates, Inc. (MTEM): Price and Financial Metrics
Molecular Templates, Inc. (MTEM)
Today's Latest Price: $11.79 USD
Updated Jan 19 4:00pm
Add MTEM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
MTEM Stock Summary
- Of note is the ratio of Molecular Templates Inc's sales and general administrative expense to its total operating expenses; only 11.5% of US stocks have a lower such ratio.
- With a price/sales ratio of 25.63, Molecular Templates Inc has a higher such ratio than 91.41% of stocks in our set.
- With a year-over-year growth in debt of 103.7%, Molecular Templates Inc's debt growth rate surpasses 88.52% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Molecular Templates Inc, a group of peers worth examining would be CRBP, KALV, NXTC, DTIL, and ORMP.
- MTEM's SEC filings can be seen here. And to visit Molecular Templates Inc's official web site, go to www.mtem.com.
MTEM Stock Price Chart Interactive Chart >
MTEM Price/Volume Stats
| Current price | $11.79 | 52-week high | $19.12 |
| Prev. close | $11.05 | 52-week low | $7.51 |
| Day low | $11.06 | Volume | 301,180 |
| Day high | $12.05 | Avg. volume | 266,878 |
| 50-day MA | $9.61 | Dividend yield | N/A |
| 200-day MA | $12.27 | Market Cap | 589.08M |
Molecular Templates, Inc. (MTEM) Company Bio
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.
Loading social stream, please wait...